Billionaire entrepreneur and Cost Plus Drugs co-founder Mark Cuban won't have to raise medicine prices, as Trump’s new ...

India emerges stronger in the US-India reciprocal tariffs scenario, negotiating favorable trade agreements and protecting ...

India expects minimal price changes for its pharma exports under new US tariffs, as punitive measures haven’t hit the sector ...

AstraZeneca Pharma India announced that it has received approval from the Central Drugs Standard Control Organization (CDSCO), Directorate General of Health Services, Government of India, to import ...

Indian equity markets react to Trump's tariffs, impacting sectors like pharma, gems, auto components, and IT services ...

Penny stocks tend to be considered high-risk, high-return stocks, and they are attractive options for investors who are ...

Commerce Minister Piyush Goyal recently sparked a debate by challenging India's startup ecosystem to move beyond delivery ...

The direct impact of higher US tariffs on India looks fluid as of now and a mutually beneficial trade deal by the end of this ...

The imposition of a 26% reciprocal tariff by the United States on Indian medical device exports has raised serious concerns ...

Although Trump’s tariffs do not directly target India’s $283 billion IT services sector, his retaliatory action has created ...

In his most expansive trade action to date, US president Donald Trump's imposed 10% "baseline" tariff on most import ...

Global stock markets plunged after President Trump announced a 10% blanket tariff on all U.S. trading partners, with higher ...